Latest news with #AbivaxSA
Business Insider
27-07-2025
- Business
- Business Insider
LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR yesterday and set a price target of $101.00. The company's shares closed last Friday at $66.49. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Slutsky is a 4-star analyst with an average return of 11.7% and a 39.25% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Celldex. Currently, the analyst consensus on Abivax SA Sponsored ADR is a Strong Buy with an average price target of $79.29, a 19.25% upside from current levels. In a report released on July 24, Morgan Stanley also upgraded the stock to a Buy with a $71.00 price target. Based on Abivax SA Sponsored ADR's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.01 million and a GAAP net loss of $47.3 million. In comparison, last year the company earned a revenue of $2.33 million and had a GAAP net loss of $95.79 million
Yahoo
11-06-2025
- Business
- Yahoo
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the 'General Meeting'), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ('Board'). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions. The shareholders have also ratified the appointment of Sylvie Grégoire as Chairman and the appointment of Dominik Höchli, MD as a Board member. Details of the vote results will be available on the Company's website ( ***** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX. Contacts:Abivax Investor RelationsPatrick 847 987 4878Sign in to access your portfolio
Business Insider
05-06-2025
- Business
- Business Insider
Abivax SA (0RA9) Receives a Buy from Kepler Capital
In a report released on June 3, Justine Telliez from Kepler Capital maintained a Buy rating on Abivax SA (0RA9 – Research Report), with a price target of €17.60. The company's shares closed yesterday at €7.01. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Telliez covers the Healthcare sector, focusing on stocks such as Valneva, Genfit, and Innate Pharma SA. According to TipRanks, Telliez has an average return of -8.4% and a 38.04% success rate on recommended stocks. Currently, the analyst consensus on Abivax SA is a Moderate Buy with an average price target of €17.60. Based on Abivax SA's latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of €94.6 million. In comparison, last year the company earned a revenue of €2.25 million and had a GAAP net loss of €95.79 million
Yahoo
02-06-2025
- Business
- Yahoo
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published: On January 9, 2025 in a press release titled 'Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment' On January 23, 2025 in a press release titled 'Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress' On January 28, 2025 in a press release titled 'Abivax Publishes 2025 Financial Calendar' On February 21, 2025 in a press release titled 'Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025' On March 24, 2025 in a press release titled 'Abivax Announces Full Year 2024 Financial Results' On March 26, 2025 in a press release titled 'Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies' On April 22, 2025 in a press release titled 'Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors' On April 22, 2025 in a press release titled 'Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones' On April 29, 2025 in a press release titled 'Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis' First Quarter 2025 Financial Highlights (IFRS figures)(Consolidated, unaudited results) Income Statement Three months endedMarch 31, Change in millions of euros 2025 2024 Total operating income 1.0 1.2 -0.2 Total operating expenses of which Research and Development costs (39.3) (35.7) (3.6) of which Sales and Marketing costs (0.9) (2.0) 1.1 of which General and Administrative costs (8.0) (8.1) 0.1 Operating loss (47.2) (44.7) (2.5) Financial (loss) income (5.2) 1.8 (7.0) Net loss for the period (52.4) (42.9) (9.5)Balance Sheet March 31, 2025 December 31, 2024 Change in millions of euros Net financial position 18.5 53.4 (34.9) of which other current financial assets and other current receivables and assets* 26.3 23.2 2.6 of which available cash and cash equivalents 103.6 144.2 (40.6) (of which financial liabilities)** (111.4) (114.0) 2.6 Total Assets 166.9 205.2 (38.3) Total Shareholders' Equity (6.6) 40.6 (47.2) * Excluding items of the liquidity contract (liquidity and own shares) and prepaid expenses** Financial liabilities include borrowings, convertible loan notes, derivative instruments, royalty certificates and other financial liabilitiesOperating loss increased by EUR 2.5M to EUR -47.2M for the three months ended March 31, 2025 compared to EUR -44.7M for the three months ended March 31, 2024. Operating income, consisting predominantly of Research Tax Credits and Subsidies, decreased by EUR 0.2M to EUR 1.0M for the three months ended March 31, 2025 compared to EUR 1.2M for the three months ended March 31, 2024. The increase in operating loss was driven by operating expenses as described further below. Research and development (R&D) expenses increased by EUR 3.6M to EUR -39.3M in the first quarter of 2025 compared to EUR -35.7M in the same period in 2024. This increase was predominantly driven by expenses related to: A EUR 3.0M, or 736% increase related to our Crohn's Disease (CD) clinical program, driven by the progression of Phase 2b clinical trials for obefazimod in CD; A EUR 2.7M, or 78%, increase in transversal activities related to the overall expansion of the R&D headcount to support our organizational growth and the issuance of new equity awards to officers and employees in R&D and Partially offset by a decrease of EUR 1.3M, or -4%, related to our Ulcerative Colitis (UC) clinical program as our Phase 3 clinical trials reached full enrollment. Sales and marketing (S&M) expenses decreased to EUR -0.9M for the three-month period ended March 31, 2025 compared to EUR -2.0M for the same period in 2024. The decrease was predominantly driven by a reduction in non-critical expenses to manage our cash expense. General and administrative (G&A) expenses decreased to EUR -8.0M for the first quarter of 2025 compared to EUR -8.1M for the first quarter of 2024. This decrease was primarily due to: A decrease in personnel costs of EUR 0.6M, resulting from the expense recognition pattern of equity awards granted to certain of our officers and employees, many of which were issued in connection with our U.S. initial public offering and listing on Nasdaq in October 2023; Offset by EUR 0.4M increase related to legal and professional fees and other costs associated with operating as a dual-listed public company. For the three-months ended March 31, 2025, our EUR -5.2M net financial loss was driven primarily by the following items: Interest expenses of EUR -3.5M in relation to borrowings and loans; Non-cash expense of EUR -1.0M in relation in relation to our royalty certificates; and Foreign Exchange losses of EUR -1.0M; Mostly offset by interest income of EUR 0.9M in relation to the invested proceeds from our U.S. initial public offering and listing on Nasdaq. Cash position as of March 31, 2025 was EUR 103.6M compared to EUR 144.2M as of December 31, 2024. The decrease was due to EUR -33.3M used in operating activities and EUR -7.8M related to principal and interest paid on our debt facilities. This decrease was partially offset by EUR 1.0M of interest received on cash. Based on the currently available funds and operating assumptions, Abivax expects to be able to finance its operating cash flow requirements into the fourth quarter of 2025. ***** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX. Contacts: Abivax Investor RelationsPatrick 847 987 4878 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company's business and financial objectives. Words such as 'design,' 'expect,' 'forward,' 'future,' 'potential,' 'plan,' 'project,' 'will' and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, Abivax's cash runway, and other statements that are not historical fact. Although Abivax's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d'Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption 'Risk Factors.' These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. and the availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
22-04-2025
- Business
- Business Upturn
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Advertisement Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as Vice President of Global Marketing for Immunology and later as Head of Global Medical Affairs. His strategic expertise in medical affairs and product positioning—particularly within competitive immunology markets—will be instrumental as Abivax prepares for the upcoming Phase 3 data readout for the 8-week induction trial in ulcerative colitis expected in Q3 2025. In addition to his experience at AbbVie, Dr. Höchli served as Interim CEO of Catapult Therapeutics, a hematology-oncology company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and currently serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit Committee and the Research & Development Committee. Sylvie Grégoire, Chair of Abivax Board of Directors, commented: 'We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical strategy and commercialization within immunology will be invaluable as we approach key clinical and regulatory inflection points for obefazimod.' Dr. Dominik Höchli added: 'I'm excited to join the Board at a time when Abivax is entering a critical phase of clinical development and to support the company's efforts to bring obefazimod to patients living with ulcerative colitis and Crohn's disease.' About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at Follow Abivax on LinkedIn and on X, formerly Twitter, Abivax. Contact: Patrick Malloy SVP, Investor Relations, Abivax [email protected] +1 847 987 4878 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company's business objectives. Words such as 'anticipate,' 'continue,' 'expect,' 'forward,' 'potential' and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, Abivax's expectations regarding the availability of data and timing of reporting results from its clinical trials, including its Phase 3 ABTECT-1 and ABTECT-2 induction trials and Phase 3 ABTECT maintenance trial, and other statements that are not historical fact. Although Abivax's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d'Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption 'Risk Factors.' These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe for, securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
